Overview
Rubedo Life Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule therapeutics that selectively target pathologic senescent cells—dysfunctional aging cells that accumulate with age and drive chronic disease. The company employs its proprietary ALEMBIC platform, an AI-driven drug discovery system, to identify and modulate specific cellular targets across multiple therapeutic areas including dermatology, pulmonary fibrosis, neurodegenerative disease, and oncology. By addressing the fundamental mechanisms of cellular aging rather than disease symptoms alone, Rubedo aims to extend human healthspan and restore biological youth at the cellular level.